Business Context and Reporting Period
The provided filing is EyeGate Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 4, 2020. The request metadata identifies Kiora Pharmaceuticals, Inc., but the source text identifies EyeGate Pharmaceuticals, Inc. and ticker EYEG.
EyeGate is a clinical-stage ophthalmic pharmaceutical company with no significant commercial product revenue. Its lead candidate, EyeGate Ocular Bandage Gel (OBG), is a modified hyaluronic-acid eye drop being developed for corneal wound healing following PRK surgery and punctate epitheliopathies, including dry eye. The company operates as one research-and-development segment and had 10 full-time employees at year-end.
Financial Performance and Position
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Collaboration revenue | $2.686 million | $1.653 million | +$1.033 million |
| Research and development expense | $5.389 million | $8.056 million | -$2.666 million |
| General and administrative expense | $4.406 million | $4.441 million | -$0.036 million |
| Total operating expenses | $9.795 million | $12.497 million | -$2.702 million |
| Other income, net | $0.108 million | $0.119 million | -$0.012 million |
| Net loss | $7.097 million | $10.811 million | Loss decreased by $3.715 million |
| Basic and diluted loss per share | $2.23 | $4.57 | Improved |
| Net cash used in operating activities | $8.154 million | $10.845 million | Use decreased by $2.691 million |
| Cash and cash equivalents at year-end | $3.777 million | $8.004 million | -$4.228 million |
Collaboration revenue in 2019 consisted of recognition of $2.686 million of deferred revenue after Bausch Health Companies terminated its two EGP-437 license agreements. No further revenue is expected from those agreements. The company has historically generated no significant product revenue and has never been profitable.
2019 research and development expense declined primarily because of lower EGP-437 activity and completion of certain OBG trials in 2018, partly offset by the OBG PRK pivotal trial and the follow-on punctate-epitheliopathy trial. A $0.500 million non-cash increase in contingent consideration was recorded based on the estimated present value of an OBG FDA-approval earn-out.
Total assets were $10.113 million and total liabilities were $3.490 million at December 31, 2019. Stockholders’ equity was $6.622 million. The company reported no indebtedness other than ordinary-course trade payables and capital lease obligations. Contractual obligations totaled $0.411 million, including $0.086 million of lease obligations and $0.325 million of licensing obligations.
Material Changes Versus the Prior Comparable Period
- Net loss improved by approximately $3.7 million, primarily due to lower operating expenses.
- Operating cash use declined by approximately $2.7 million, but year-end cash fell by approximately $4.2 million because financing proceeds were substantially lower than in 2018.
- R&D expense declined 33%, while collaboration revenue increased 63%; the revenue increase was nonrecurring and resulted from termination of the Bausch Health agreements.
- Bausch Health terminated both EGP-437 license agreements effective March 14, 2019, returning the platform rights to EyeGate. Further EGP-437 development is on hold.
- EyeGate completed a 1-for-15 reverse stock split effective August 30, 2019, allowing it to regain compliance with Nasdaq’s minimum bid-price rule.
- In October 2019, the company raised approximately $1.9 million gross through a related-party private placement of common stock and warrants and received $2.150 million from warrant exercises.
- In January 2020, the company completed a registered direct offering that generated approximately $4.5 million of net proceeds.
Clinical Outlook, Risks, and Unusual Items
- The pivotal PRK study enrolled 234 patients. OBG achieved complete wound closure in 80.2% of eyes at Day 3 versus 67.0% for the bandage-contact-lens control, with a p-value of 0.0203. Average Day 2 wound size was 46% smaller with OBG.
- Management planned to submit an FDA de novo application for OBG commercialization for the PRK indication in the first half of 2020.
- A follow-on punctate-epitheliopathy trial was initiated in the third quarter of 2019, with topline data expected in the first half of 2020. Subject to positive results and FDA discussions, a pivotal study was planned for the second half of 2020.
- Management was evaluating combining OBG with an off-patent antibiotic or anti-inflammatory and planned, subject to a positive outcome, to initiate a Phase 2 study by year-end 2020.
- The auditor’s report included an explanatory paragraph regarding substantial doubt about the company’s ability to continue as a going concern. Management stated that year-end cash plus the January 2020 offering proceeds was expected to fund planned operations through December 31, 2020, but additional capital will be required.
- Key risks include failure to obtain regulatory clearance, unfavorable or inconclusive clinical results, dependence on third-party manufacturers and clinical research organizations, limited cash resources, potential dilution from future financings, reimbursement uncertainty, competition, and intellectual-property challenges.
- The company had no material off-balance-sheet arrangements. A $1.710 million contingent-consideration liability remained at year-end, reflecting the estimated OBG FDA-approval earn-out.
- Armistice Capital affiliates held approximately 39% of outstanding voting power and also held convertible preferred stock and warrants, creating significant ownership concentration.
Important Facts for Investors to Verify
- Confirm that the issuer is EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals, Inc., and reconcile the filing identity with the intended investment.
- Verify the status and outcome of the planned OBG de novo FDA submission, including whether clearance was obtained and on what terms.
- Assess actual cash burn and financing activity after December 31, 2019, including the company’s ability to fund operations beyond the stated December 31, 2020 horizon.
- Review the going-concern disclosure, auditor’s explanatory paragraph, contingent-consideration liability, and remaining licensing commitments.
- Evaluate dilution from outstanding warrants, preferred stock convertible into 852,500 common shares, stock options, and future equity financings.
- Confirm clinical-trial results, safety data, regulatory endpoints, manufacturing readiness, and the commercial viability of OBG relative to existing post-PRK care.